Drugs / voxtalisib
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT01596270 | Jun 2012 → Oct 2014 | cancer | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01410513 | Dec 2011 → May 2014 | B-cell chronic lymphocytic leukemia, mantle cell lymphoma | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01390818 | May 2011 → Apr 2015 | breast cancer, colorectal cancer, melanoma, metastatic neoplasm +1 | EMD Serono | Completed | No outcome recorded |
| Phase 1 | NCT01240460 | Jan 2011 → Jun 2012 | astrocytoma (excluding glioblastoma), glioblastoma | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT00704080 | Aug 2008 → Feb 2012 | glioblastoma, mixed glioma | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT00777699 | Aug 2008 → Feb 2011 | non-small cell lung carcinoma | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT00485719 | Jun 2007 → Sep 2012 | cancer | Sanofi | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01587040 | Jul 2012 → May 2018 | cancer | Sanofi | Completed | No outcome recorded |
| Phase 1/2 | NCT01082068 | Jun 2010 → Apr 2013 | breast cancer | Sanofi | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01936363 | Sep 2013 → May 2015 | ovarian cancer | EMD Serono | Completed | No outcome recorded |
| Phase 2 | NCT01403636 | Oct 2011 → Sep 2014 | lymphoma | Sanofi | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2010-06-06 | Exelixis | Results Exelixis Reports Updated Data from Multiple Clinical Trials of the Dual PI3K and mTOR Inhibitor XL765 (SAR245409) to be Presented at ASCO exelixis.com ↗
Exelixis, Inc. (Nasdaq: EXEL) today reported updated interim data from three ongoing trials of XL765 (SAR245409), an orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mTOR. |
| 2009-06-01 | Exelixis | Results Exelixis Reports Encouraging Phase 1 Data To Be Presented at ASCO for XL765, a Dual Inhibitor of PI3K and mTOR exelixis.com ↗
Exelixis, Inc. (Nasdaq:EXEL) today reported encouraging data from an ongoing Phase 1 dose-escalation trial of XL765 in patients with solid tumors. |
All press releases naming this drug 3 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | voxtalisib | “We aimed to investigate the efficacy and safety of voxtalisib (also known as XL765 or SAR245409), a pan-PI3K/mTOR inhibitor, in patients with relapsed or refractory lymphoma,...” PMID 29550382 ↗ Mar 2018 |
| Known as | SAR245409 | “XL765 (SAR245409) is a dual PI3K and mTOR inhibitor.” NCT01240460 ↗10“XL765 (SAR245409)” NCT00485719 ↗ “XL765 (SAR245409)” NCT00704080 ↗ “XL765 (SAR245409)” NCT01082068 ↗ “XL765 (SAR245409)” NCT00777699 ↗ |
| Known as | XL765 | “We aimed to investigate the efficacy and safety of voxtalisib (also known as XL765 or SAR245409), a pan-PI3K/mTOR inhibitor, in patients with relapsed or refractory lymphoma,...” PMID 29550382 ↗ Mar 2018 |
| Action | Inhibit | “XL765 is a new chemical entity that inhibits the kinases PI3K and mTOR” NCT00485719 ↗ |
| Modality | Small molecule | “XL765 is a new chemical entity” NCT00777699 ↗ |
| Route | Oral | “administered orally” NCT00485719 ↗ |
| Target | MTOR | “XL765 is a new chemical entity that inhibits the kinases PI3K and mTOR.” NCT00777699 ↗ |